By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Technologiepark 4

Ghent  Zwijnaarde  9052  Belgium
Phone: 32-0-9-261-06-32 Fax: 32-0-9-261-06-28


Company News
Ablynx (ABLYF) Will Announce Its 2017 Half Year Results With Webcast On 24 August 2017 8/17/2017 10:18:12 AM
Ablynx (ABLYF) Announces Warrant Exercise 8/11/2017 10:49:07 AM
Ablynx (ABLYF) Receives Fast Track Designation From The FDA For Caplacizumab For The Treatment Of Acquired TTP 7/26/2017 10:36:47 AM
Ablynx (ABLYF) Announces Warrant Exercise 7/24/2017 11:38:05 AM
Ablynx (ABLYF) Seals Nanobody R&D Deal Worth $2.8 Billion With Drug Giant Sanofi (SNY) 7/20/2017 6:33:49 AM
Ablynx (ABLYF) Proposes Appointment Of Mrs. Hilde Windels As A New Independent Director 7/17/2017 10:45:18 AM
Ablynx (ABLYF) Initiates A Single And Multiple Dose Phase I Study Of Caplacizumab In Healthy Japanese Subjects 6/26/2017 12:38:26 PM
Novel Nanobody To Start Clinical Development In Osteoarthritis - Ablynx (ABLYF) To Receive €15 Million Milestone Payment 5/22/2017 10:40:28 AM
Ablynx (ABLYF) Reports Financial Results For The First Three Months Of 2017 And A Year-To-Date Business Update 5/11/2017 12:47:40 PM
Ablynx (ABLYF) Completes Patient Recruitment In Its Phase III Hercules Study Of Caplacizumab For The Treatment Of aTTP 5/2/2017 11:02:06 AM